|
4 documents found matching dt:diagram.
|
|
Prev
Next
|
|
|
|
Showing 1-4 of 4 documents
|
1.
Organizational charts re marketing & sales
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
Merck Organization Chart Focusing on Marketing and Sales
Medical Affairs Louis SherWood
Huitiah Health Afnefrìcas 'i David AhstioeV ', ' ' Wéhdy Dixöh' ' '
Arthritis & Analgesie FBG Adam Sdhechter
Oust Mafketíno'&'Sálés, Margaret Mcëiyhri
Vioxx Prtimotíoh/Sáles 'Thomas Cannell
<*'/s*s.
'
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx07l10
|
|
| |
2.
Gabapentin and Tramadol: New Analgesics, Better Analgesics?
|
Document Date:
|
00000000
|
|
Author:
|
Manning, Donald C
|
|
Corporate Author:
|
University of Virginia
|
|
Search Terms in Context:
|
GABAPENTIN AND TR MADOL: NSW ANALGESICS, BETTER ANALGESICS?
Donald C. Manning, M.D., Ph.D.
University of Virginia
The ideal analgesic is yet to be developed. The interest in new and potentially more
effective agents is reflected in the enthusiasm that meets a newly released potential analgesic.
Aside from of icacy we are seeking agents with convenient dosing, minimal adverse effects and
lack of toxicity. Two unique agents that have recently entered into the armamentarium of the pain
management specialist are gabapentin and tramadol.
GABAPENTLN (Neurontin) Gabapentin is one of the new generation anticonvulsant
agents derived from GABA with a unique action. It was originally released in 1994 as add-on
therapy to other anticonvulsants for refractory seizures. Despite the intentional synthesis of
gabapentin as an analogue of GABA it has no affinity for the GABA receptor. it does however
have excellent penetration through the blood brain barrier secondary to its lipophilicity. The
mechanism of action of gab
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/pcb00a10
|
|
| |
3.
Neurontin Marketing Assessment
|
Document Date:
|
19960731
|
|
Author:
|
Boris, John T
|
|
Search Terms in Context:
|
pgNbr=1
CONFIDENTIAL
DISTRIBUTION:
NPC Committee:
D. Canter
R. Cresswell
P. Cuatrecasas
L. de Vink
F. Hershenson
H. Kaplan
W. Merino
J. Pieroni
C. Wheeldon
W. Wierenga
A. Wild
R. Zerbe
Marketing Council:
F. Anton
W. Brandner
N. Cadre
J. Evans
M. Montanan
R. Oliva
L Perlow
1. Summers
jbmem\rnktg-ass.neu17/39 /96
Ann Arbor
Ann Arbor
Ann Arbor
MOPS
Ann Arbor
Ann Arbor
Ann Arbor
MOPS
MOPS
Ann Arbor
MOPS
Ann Arbor
Spain
Germany
France
UK
Italy
Canada
USA
Belgium
Development Team:
H. Bockbrader
J. Boonstra
J. Boris
A. Brankiewicz
M. Dong
E. Garofalo
K. Harris
L Magnus-Miller
R. Martin
G. Menard
G. Murray
C. Taylor
J. Turner
J. Knoop
R. Walker
J. Zeller
cc: O. Brandicourt
A. Panda
M. Pierce
M. Renshaw
D. Saltel
C. Saratsis
Ann Arbor
MOPS
MOPS
Ann Arbor
Ann Arbor
Ann Arbor
Ann Arbor
MOPS
Ann Arbor
MOPS
Germany
Ann Arbor
Ann Arbor
MOPS
Ann Arbor
Holland
MOPS
Ann Arbor
MOPS
MOPS -
MOPS
Japan
N
V082736
pgNbr=2
CONFIDENTIAL
Morris Pla:rs. AU
FWKE-DAVIS
m* Who Care
Me
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/pca00a10
|
|
| |
4.
A Saturable Transport Mechanism in the Intestinal Absorption of Gabapentin is the Underlying Cause of the Lack of Proportionality between Increasing Dose and Drug Levels in Plasma
|
Document Date:
|
19920616/e
|
|
Author:
|
Thompson, Paul R|Stewart, Barbara H|Kugler, Alan R|Bockbrader, Howard N
|
|
Search Terms in Context:
|
pgNbr=1
I
I
Phasmecei al Research. Vol. 10. No. 2. 1993
A Saturable Transport Mechanism in
the Intestinal Absorption of
Gabapentin Is the Underlying Cause of
the Lack of Proportionality Between
Increasing Dose and Drug Levels
in Plasma
Barbra H. Stewart," Alan IL Kugler,'
Paul R. Thompson,' and Howard N. Bockbrader'
Received Jane 16. 1992: accepted August 22. 1992
Gabapentin (1-(anrinomethyl)cyelohexaneacetic acid) is a neuropro-
tective agent with antiep0cptic properties. The structure is small
(molecular weight less than 200). is zwitterionic. and resembles an
amino acid with the exception that it does not contain a chiral car-
bon and the amino group is not alpha to the carboxylate fbnction-
ality. Gabapentin is not metabolized by humans, and thus, the
amount of pbapentin excreted by the renal route represents the
fraction of dose absorbed. Clinical trials have reported dose-
dependent bioavailabilities ranging from 73.8 c 18.3 to 35.7 = 18.3%
when the dose was increased from 100 to 1600 mg. The pe
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/mcb00a10
|
|
| |
|
Prev
Next
|
